Keryx Biopharmaceuticals (NASDAQ:KERX) will release its Q2 2013 earnings data before the market opens on Thursday, August 01st. Persons that wish to register for the company’s earnings conference call can do so using this link.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.03) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.01) by $0.02. The company had revenue of $7.00 million for the quarter, compared to the consensus estimate of $5.83 million. During the same quarter last year, the company posted ($0.13) earnings per share. On average, analysts expect Keryx Biopharmaceuticals to post $-0.33 EPS for the current fiscal year and $0.02 EPS for the next fiscal year.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded up 0.66% during mid-day trading on Wednesday, hitting $9.19. Keryx Biopharmaceuticals has a 52 week low of $1.68 and a 52 week high of $9.98. The stock’s 50-day moving average is currently $8.04. The company’s market cap is $751.0 million.
Several analysts have recently commented on the stock. Analysts at JPMorgan Cazenove initiated coverage on shares of Keryx Biopharmaceuticals in a research note to investors on Wednesday, June 19th. They set an “overweight” rating and a $13.00 price target on the stock. On the ratings front, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Keryx Biopharmaceuticals in a research note to investors on Wednesday, June 19th. They now have a $13.00 price target on the stock. Finally, analysts at Oppenheimer reiterated an “outperform” rating on shares of Keryx Biopharmaceuticals in a research note to investors on Friday, May 17th. They now have a $12.00 price target on the stock, up previously from $11.00.
Eleven investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $11.82.
Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.